|
|||||||||
|
|||||||||
|
|||||||||
3/30 Breaking: Walmart Has Humana in its Shopping Cart
Walmart is reportedly in early-stage acquisition talks with Humana .... The news comes amid a rush of deal chatter as insurers are under pressure to lower medical care costs. .... CNBC
3/30 Gottlieb to Push FDA into Broad New Roles in Food and Diet
FDA to consider what 'healthy' means and other claims food companies can make .... The agency plans to explore what it means for food products to be considered healthy and may create an icon or symbol to label those that meet the possible new definition .... CNBC
3/30 Never Eat Anything Bigger Than Your Head: Why Takeda Might Not Be Able to Swallow Shire
Takeda Shares Fall as Investors Queasy Over Possible Bid for Shire .... At current share prices, it would mean Takeda was trying to take over a company larger than itself. Its market value as of Thursday's close was about $38 billion. London-listed Shire, which has its headquarters in Ireland but does most of its business in the U.S., closed Wednesday with a value of roughly $45 billion .... WSJ$$
3/30 Walgreens New Store Pilots Emphasize Services
Walgreens Readies New Store Formats As Amazon And CVS Loom .... Walgreens Boots Alliance will unveil a new format in pilot stores over the coming months that will bring together retail, healthcare and other services currently offered separately in some stores .... Forbes/Bruce Japsen
3/30 Cards Close to Chest on Brexanolone Pricing
Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug 'fairly' .... The theory behind the postpartum treatment is that the condition is caused by an imbalance of certain chemicals in the brain.... Sage Therapeutics believes brexanolone "corrects that rapidly and acutely." .... CNBC
3/30 Lilly Pain Pipeline: Galcanezumab, Tanezumab, Lasmiditan
Lilly's bet on pain stands out amid bare pharma pipeline .... Over the next three years, the Indianapolis drugmaker hopes to make a mark by bringing three therapies to market for pain. Among major U.S. pharma companies, Lilly's push to develop novel non-opioid painkillers is relatively unique .... BioPharma Dive
3/30 Pundit Says No Way AbbVie Can Come Close to Replacing Humira Revenue
AbbVie Has a Growing Credibility Problem .... Abbvie said in October it could see more than $35 billion in risk-adjusted sales from non-Humira medicines in 2025, and as much as $47 billion if things go especially well. The company generated $28.22 billion in sales last year, with $18.4 billion coming from Humira, the world's best-selling drug. .... Bloomberg Gadfly
3/30 Broader Indication for Blincyto
FDA Approves Blinatumomab for MRD+ ALL .... Blinatumomab was previously approved by the FDA for the treatment of adult and pediatric patients with relapsed or refractory B-cell precursor ALL. The accelerated approval of blinatumomab for MRD-positive is contingent upon confirmatory results .... OncLive
3/30 FDA Puts Drug Info in an App
FDA launches mobile app to improve access to information about drugs .... Currently, the Drugs@FDA webpage is available for patients to search for information about FDA approved drug products including patient information, drug labelling, approval letters, reviews and other information. The new mobile app will be a streamlined version of this site .... EPM
3/30 FDA Antibiotic Tool
New FDA Web Tool Will Help Doctors Prescribe the Right Antibiotic .... The FDA has recently launched a new website for sharing data points known as breakpoints. These breakpoints help identify the drugs that will be most effective in treating a given bacterial infection .... Pew Trusts
Direct link: FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria
3/30 1 in 4 Health Dollars in US Goes to Patients with Diabetes
Diagnosing Diabetes: How Much Did it Cost in 2017? .... The sum included included $237 and $90 billion in direct medical costs and reduced productivity.... The average medical expenditures were ~$16,750 per year for people with diagnosed diabetes, with ~$9,600 attributed to diabetes .... HealthDay News/MPR
3/30 Ozempic Weight Loss Results Presented at Endocrine Society; Tops Saxenda Comparator
Can a Diabetes Drug Help Obese People Lose Weight? .... About 65 percent of participants taking semaglutide lost at least 10 percent of their body weight, compared to only 10 percent from the placebo group and 34 percent in the liraglutide group. .... Healthline
Tweet of the Day
You betcha! Per @FAIRHealth, #retail #pharmacy #clinics are most popular in Minnesota, New Jersey and Alaska https://t.co/8ICxFJJfTQ pic.twitter.com/xGySVKQquh
— Adam J. Fein (@DrugChannels) March 29, 2018
3/30 Internet Drug News Fast Takes:
Teva launches generic version of Shire's top-selling internal medicine
BioPharma Dive
Pfizer's rare heart disease drug succeeds in late-stage study
Reuters
Faced with fresh concerns about Hemlibra's safety, Roche spells out what it knows about 5 deaths
Endpoints News
Abbott invests in diabetes care start-up
CNBC
Health-Care M&A Balloons in Busiest Start in More Than a Decade
Bloomberg
|
|
3/29 Shulkin Out
Veterans Affairs Secretary Is Latest to Go as Trump Shakes Up Cabinet .... The announcement punctuated what has been a sharp fall from favor for Dr. Shulkin, a politically moderate former hospital executive, who delivered Mr. Trump a string of bipartisan legislative victories at a time when he was struggling to find them .... NY Times
3/29 Advancing Biosimilars at Top of Gottlieb's To-Do List
FDA working on a 'dozen' policies to boost copycat biotech drugs .... Gottlieb said he was concerned about the impact of deals like the CVS Health purchase of Aetna on the ability of pharmaceutical companies to block the entry of cheaper copycat drugs .... Reuters
3/29 Doctors Were Using Teva's Coreg Generic for an Indication Still Covered by Glaxo's Patent. Glaxo Sued and Lost
Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict .... The judge said there wasn't enough proof Teva caused doctors to prescribe the generic for congestive heart failure. Instead, there was evidence that doctors were relying on other information .... Bloomberg
3/29 Shire Now in Play on Takeda Interest; Will Anyone Else Bid?
UPDATED: Shire shares rocket up after Takeda says it's pondering a takeover bid .... For Takeda CEO Christophe Weber, a Shire acquisition would drive a big expansion in the Boston area, where the Japanese company has been concentrating much of its R&D operations .... Endpoints News
3/29 Proving the Value of a Drug Costs a Lot of Time and Dollars
In Battle To Cut Drug Prices, Outcome-Based Pricing Carries Big Risks For Biopharma .... Without robust outcomes data, you might get FDA approval, but you'll never get buy-in from payers. This is a big difference in the R&D landscape from not too long ago when FDA approval was the major hurdle .... Forbes/John LaMattina
3/29 Golden State Price Hike Law Sees Frequent Players Valeant and Teva
California's drug transparency law yields early surprises .... Advance notice of drug price hikes finds increases up to 63 percent, but whether public pressure will make a difference won't be known for a while .... Politico
3/29 Health Plan Uses Script-Shaming to Cut Painkiller Use
Cigna Says It Reduced Opioid Use By 25% .... Cigna says that the reduction was not caused by simply denying claims for opioids, but by its staff physicians carefully reaching out to doctors to make sure they understood how their prescribing behavior compared to the recommendations of the Centers for Disease Control and Prevention and the behavior of other prescribers .... Forbes/Matthew Herper
3/29 Study Claims Drug-Resistant Infections Amount to an extra $1,383 on Every Hospital Bill. Problem Persists Because Docs Don't Want to Deny Antibiotics
The Yelping of the American Doctor .... Online patient surveys are driving doctors to overprescribe antibiotics, and it's making us all sick .... Wired
3/29 Symfi, a New Triple Combo for HIV
FDA Gives Mylan's New HIV Drug a Thumbs-Up .... FDA has approved Mylan NV's Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients who weigh at least 40 kilograms .... Biospace
3/29 Snapchat Your Statin
Selfie Medicine: Phone Apps Push People to Take Their Pills .... Selfie medicine works like this: Open an app on your phone, show your pills, put them in your mouth and swallow. Don't forget to show your empty mouth to the camera to prove today's dose is on its way. Then upload the video proof to the clinic .... NY Times
3/29 Internet Drug News Fast Takes:
FDA to USP: Biological Product Monographs Could Delay Biosimilar Approvals
Regulatory Focus
Edge to Cut Jobs as Head Injury Drug Flops in Phase 3, Shares Tumble
Xconomy
Tesaro posts mixed Phase 2 data for Zejula combo
BioPharma Dive
Esperion bolsters cholesterol drug with new combo data
BioPharma Dive
Colon cancer screening rates vary widely across U.S.
Reuters
3/28 1.6 Million Elderly Pain Patients Will be Cut Off by New Medicare Regs
Medicare Is Cracking Down on Opioids. Doctors Fear Pain Patients Will Suffer. .... The rule means Medicare would deny coverage for more than seven days of prescriptions equivalent to 90 milligrams or more of morphine daily, except for patients with cancer or in hospice .... NY Times
3/28 Deaths of Hemlibra Patients Spark Warning Messages
Hemophilia patients warned of 5 deaths among patients taking Roche's big new blockbuster Hemlibra .... "Genentech has limited information about the circumstances surrounding these deaths. However, as reported by Genentech, these deaths have all been deemed unrelated to Hemlibra by the investigator or treating physician" (from a statement from Hemophilia Federation of America) .... Endpoints
3/28 Like UnitedHealth, Aetna Will Pass Drug Rebates to Members in Employer-Sponsored Plans
Aetna will pass drug discounts along to some members at the pharmacy counter .... The policy will be applied to Aetna's employer-sponsored group health plans, benefiting an estimated three million individuals. The population makes up a minority share of Aetna's 22.2 million medical members. .... Marketwatch
3/28 Glaxo Buys Out Partner Novartis in OTC Business
GSK Gets Full Control of Sensodyne Maker for $13 Billion .... Chief Executive Officer Emma Walmsley's Glaxo agreed to pay $13 billion for Novartis's stake in a joint venture that includes Panadol pain relievers and Theraflu cold remedies. The agreement gives Novartis's Vas Narasimhan more firepower for the Swiss giant's drug business and acquisitions .... Bloomberg
3/28 Market Skeptical on Cigna-Express Scripts Takeover; Cigna Says 'Full Speed Ahead'
Five Takeaways About Cigna's Strategy for Express Scripts .... Cigna plans revenue growth of 6% to 8%, and expect to find $600 million in "administrative synergies" .... Drug Channels
3/28 Glucose Monitoring System Approved, Can Be Used with Other Devices
FDA approves DexCom's glucose monitoring system .... The FDA has approved DexCom Inc's monitoring system to check blood sugar levels in children and adults suffering from diabetes, which can be used along with devices such as insulin pumps. .... Reuters
3/28 Opdivo-Yervoy Combination for mCRC Filed with FDA
FDA Accepts Bristol-Myers Combo Application .... The biologics license is for the drug combination for adults with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan .... Biospace
3/28 #DataMining Twitter and Support Communities for Side Effects
How Social Media Can Reveal Overlooked Drug Reactions .... Doctors and drug companies are analyzing social networks to get a faster, wider look into how patients react to drugs, sometimes picking up information about side effects that clinical trials missed. .... NPR
3/28 Inspiring Story of Kathy Giusti and the Multiple Myeloma Research Foundation
She Was Given Three Years To Live. So She Transformed Cancer Research .... Giusti's survival has a lot to do with luck. Cancer is unpredictable. But it's also in part due to the philanthropic organization she founded in 1998, the Multiple Myeloma Research Foundation. The MMRF has helped accelerate ten myeloma drugs to market, from Takeda's Velcade to Johnson & Johnson's Darzalex, by speeding up clinical trials .... Forbes/Ellie Kincaid
3/28 Novo Nordisk, J&J, Novartis Lead in Social Engagement
Pharma's social media strategies are growing up—and working better, too, report finds .... Leading the pack in terms of engagement was Novo Nordisk, which also ranked at the top of the last Social Check-up in 2016, growing its weighted engagement score by 13%. Novo Nordisk was followed by J&J, with an increase of 111% in its engagement score, and Novartis, which jumped 77% over its 2016 score .... Fierce Pharma
3/28 Internet Drug News Fast Takes:
Novartis touts U.S. filing plans for MS drug as patent losses loom
Reuters
Testing for hepatitis C lags with baby boomers despite high infection rate
Washington Post
Novartis CEO Aims to Double China Sales on Faster Drug Approvals
Bloomberg
Newly discovered organ may aid in cancer diagnosis
CNBC
A new poll found that a majority of Americans support a radical change to the US healthcare system
Business Insider via MSN
|
Site Map | Privacy Policy | Contact Webmaster |
||